Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AssigneeAgenebio, Inc.
InventorsBelew Mekonnen, John A. Butera, Jianxing Huang
Life of this patent
Estimating the term…
Loading patent…
AssigneeAgenebio, Inc.
InventorsBelew Mekonnen, John A. Butera, Jianxing Huang
Estimating the term…
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
A compound of formula II:
A compound of formula II:
A compound selected from:
Dependencies are inferred from the claim text.